Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.
about
TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancersPrognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature ReviewMolecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and diseaseMolecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary fieldPhenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survivalColorectal Cancer Biomarkers: Where Are We Now?HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.CpG Island Methylator Phenotype-High Colorectal Cancers and Their Prognostic Implications and Relationships with the Serrated Neoplasia PathwayEpigenetics in diagnosis of colorectal cancerThe more the messier: centrosome amplification as a novel biomarker for personalized treatment of colorectal cancersThe Emergence of Pan-Cancer CIMP and Its Elusive InterpretationAssessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectumReduced FHIT expression is associated with mismatch repair deficient and high CpG island methylator phenotype colorectal cancer.Integrating Colon Cancer Microarray Data: Associating Locus-Specific Methylation Groups to Gene Expression-Based Classifications.Unsupervised Analysis of Array Comparative Genomic Hybridization Data from Early-Onset Colorectal Cancer Reveals Equivalence with Molecular Classification and Phenotypes.18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sampleDietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk studyDistinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system.Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features.The CpG island methylator phenotype (CIMP) in colorectal cancer.The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastasesPTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome.Serrated adenocarcinoma morphology in colorectal mucinous adenocarcinoma is associated with improved patient survival.A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers.Biomarker correlation network in colorectal carcinoma by tumor anatomic location.Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiencyDNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancerA cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis.Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP).Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reactionEpigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma.B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP).A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases.CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.NRAS mutations are rare in colorectal cancer.Interpretation of genome-wide infinium methylation data from ligated DNA in formalin-fixed, paraffin-embedded paired tumor and normal tissue.Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.
P2860
Q24288715-7B4368D1-D9C4-47E1-9142-0E1D2A1D0D64Q24289005-AAC6E8FC-E6A3-4539-9216-88097BBF0679Q24289344-60655E75-4843-4BFF-B54E-BF6B5A8DDD31Q24620628-D31238BF-D97C-4B78-A4E3-4191C2957193Q24626799-A7733034-2DF6-49C4-8F57-B9022DBC3825Q27003134-D5B12A6B-C884-4198-9C8F-5D87E841B8CEQ27851557-4C923ED0-A1C1-4EFC-AA17-F0C2C85DF82DQ28066004-840A475D-1EC2-4ED7-A5A5-FBF2030FEA8AQ28071714-89944FB2-6144-48EB-B679-2D36FD7BA726Q28072910-8C2350FD-4993-4AA7-8C5C-3D291D014AA1Q28075374-FC45D141-533C-4367-ACC2-63ACB5705E11Q28262150-F3ECC50B-68D3-49FB-920A-617D62125261Q30543686-7736D7AC-AC41-44F4-9033-5DE6A9C6EDDFQ31127007-5E2CD223-80CA-4B38-BAF1-6584B8C335A5Q31149689-BD0BF27B-20E7-4F9F-8F13-5293E95B4540Q33283458-5B30F4A0-24E3-4BF3-B7B6-8E2FADC88BC1Q33383866-90A9AA1F-39D3-403C-93FB-C1C0DBECF834Q33541307-3C1F5BDD-6E77-40BC-9392-92F9C68C3D88Q33577619-2CC11EB8-D5B9-418C-9161-B236A6265F56Q33584274-33F5FB4A-6F30-4E3F-B9E5-B57FF43CF7A8Q33596629-A9B72DE2-12E7-4A0E-B807-8233635FEE31Q33630343-2C9714BA-4FF9-44DF-897E-C01E951BC99AQ33723499-0C1721DF-FAA7-426B-B95A-D7C234020F8DQ33769492-0834E96E-E338-47DA-A9D5-FC18AFFCFEAEQ33798773-85CC6872-7604-4499-8385-4596E2242BCDQ33808550-AE89EE5D-B5DF-4EF4-9D57-4F2A7B9CCA5FQ33808553-0B6CEF6D-2E8C-42E8-A1D7-F63C74133FBBQ33811768-8D6023A1-BCAA-4A44-A180-0E37B623DD62Q33837632-0DE1CACD-1E31-4D33-8C40-F864AADCC134Q33837712-D042BA2C-70EA-40B9-A6EA-09177EEB3710Q33869180-4B8D9E6F-E419-404A-8E95-ED693B418DF2Q33883829-A71B2044-EA28-4AF0-8921-8016562020EDQ33942280-DCB35284-9414-45A0-AABE-BF44B5F45412Q33947056-C68079BA-D036-4115-ACFC-F8261E964594Q33954696-FCDB3D87-89EB-447C-88FE-4DCDB5BEFF72Q34066685-7BC2F1AE-0F25-4783-AE3C-46494F16B165Q34084652-33837E04-A9CB-4E23-ABE8-87AE9BE0320BQ34091172-7B83D6C9-8C7B-473F-B212-539F0DA7BBA3Q34167124-ED4846FE-24FA-4F07-9A8C-B5D90152341AQ34217637-6AA10302-16F5-4C7A-B114-82DE71E24F48
P2860
Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Evaluation of markers for CpG ...... large population-based sample.
@ast
Evaluation of markers for CpG ...... large population-based sample.
@en
type
label
Evaluation of markers for CpG ...... large population-based sample.
@ast
Evaluation of markers for CpG ...... large population-based sample.
@en
prefLabel
Evaluation of markers for CpG ...... large population-based sample.
@ast
Evaluation of markers for CpG ...... large population-based sample.
@en
P2093
P2860
P50
P1476
Evaluation of markers for CpG ...... large population-based sample.
@en
P2093
Gregory J Kirkner
Shuji Ogino
Takako Kawasaki
P2860
P304
P356
10.2353/JMOLDX.2007.060170
P577
2007-07-01T00:00:00Z